• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24962 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     Canary Health Service [Molecular urine-based biomarkers for the diagnosis of urothelial carcinoma]
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Benefits and risks of using laparoscopic ultrasonography versus intraoperative cholangiography during laparoscopic cholecystectomy for gallstone disease
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endograft fixation]
2024     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of tezepelumab (Tezspire)]
2024     National Institute for Health and Care Excellence (NICE) Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments. NICE technology appraisal guidance 970
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Radiofrequency catheter ablation using in-silico modelling in atrial fibrillation]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Interventions to prevent aspiration pneumonia in non-ventilated hospitalized patients
2024     National Institute for Health and Care Excellence (NICE) Remdesivir and tixagevimab plus cilgavimab for treating COVID-19. NICE technology appraisal guidance 971
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (TNBC, neoadjuvant and adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2024     Canary Health Service [Assessment of body composition using electrical bioimpedance for the evaluation of overweight and obesity in primary care]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Emotional freedom technique]
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over. NICE technology appraisal guidance 967
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capivasertib (breast cancer) – benefit assessment according to §35a Social Code Book V]
2024     Canary Health Service [Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnea]
2024     Scottish Health Technologies Group (SHTG) Genotype testing to guide antibiotic use and prevent hearing loss in neonates
2024     National Institute for Health and Care Excellence (NICE) Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal). NICE technology appraisal guidance 969
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Molecular characterization of central nervous system tumors by (next-generation sequencing, NGS). Evaluation of diagnostic and prognostic utility and implementation considerations]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Magnetic resonance imaging-guided transurethral ultrasound ablation of localized prostate cancer]
2024     National Institute for Health and Care Excellence (NICE) Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 968
2024     National Institute for Health and Care Excellence (NICE) Eplontersen for treating hereditary transthyretin-related amyloidosis. NICE technology appraisal guidance 1020
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Less invasive surfactant administration]
2024     Scottish Health Technologies Group (SHTG) FDG-PET imaging in the diagnosis of dementia
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal). NICE technology appraisal guidance 966
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE technology appraisal guidance 1017
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Project A24-71]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based diagnostic assistant test for paroxysmal atrial fibrillation using 12-lead electrocardiogram data]
2024     NIHR Health Technology Assessment programme Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation
2024     National Institute for Health and Care Excellence (NICE) Single-step scaffold insertion for repairing symptomatic chondral knee defects. NICE interventional procedures guidance 793
2024     National Institute for Health and Care Excellence (NICE) Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. NICE technology appraisal guidance 1018
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – Addendum to Project A24-73]
2024     Canary Health Service [Psychological interventions in paediatric population eligible for palliative care and their family]
2024     Ontario Health Plasma-based comprehensive genomic profiling DNA assays for non-small cell lung cancer
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based screening test for emergent large vessel occlusion using non-contrast brain CT images]
2024     NIHR Health Technology Assessment programme Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
2024     National Institute for Health and Care Excellence (NICE) Phrenic nerve pacing for congenital central hypoventilation syndrome. NICE interventional procedures guidance 790
2024     National Institute for Health and Care Excellence (NICE) Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over. NICE technology appraisal guidance 1019
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole (aspergillosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Canary Health Service [Cost-effectiveness of neonatal screening for spinal muscular atrophy and severe combined immunodeficiency]
2024     Ontario Health Single-exposure, dual-energy subtraction flat panel x-ray detectors
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aging in place
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Monocyte distribution width, MDW]
2024     NIHR Health Services and Delivery Research programme Improving support and planning ahead for older people with learning disabilities and family carers: a mixed-methods study
2024     National Institute for Health and Care Excellence (NICE) Caval valve implantation for tricuspid regurgitation. NICE interventional procedures guidance 791
2024     National Institute for Health and Care Excellence (NICE) Elafibranor for previously treated primary biliary cholangitis. NICE technology appraisal guidance 1016
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole (mucormycosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Ontario Health Interferon-gamma release assay testing for latent tuberculosis infection
2024     WorkSafeBC Safety and efficacy / effectiveness on the placement of permanent catheter for marcaine infusion to treat radial nerve injury post-de Quarvain tenosinovitis surgery: 2024 update
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Biologic drugs for severe asthma
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Gastrointestinal bleeding control using endoscopic hemostatic powder]
2024     NIHR Health Technology Assessment programme Comparison of surgical or non-surgical management for non-acute anterior cruciate ligament injury: the ACL SNNAP RCT
2024     National Institute for Health and Care Excellence (NICE) Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury. NICE interventional procedures guidance 792
2024     National Institute for Health and Care Excellence (NICE) Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer. NICE technology appraisal guidance 1014
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polihexanide (Acanthamoeba keratitis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Ontario Health Peripheral nerve stimulation for chronic neuropathic pain
2024     WorkSafeBC Efficacy / effectiveness of platelet rich plasma in treating Sinus Tarsi Syndrome
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine formulations for opioid use disorder
2024     NIHR Health Services and Delivery Research programme Service innovations for people with multiple long-term conditions: reflections of a rapid evaluation team
2024     National Institute for Health and Care Excellence (NICE) Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus. NICE interventional procedures guidance 789
2024     National Institute for Health and Care Excellence (NICE) Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1015
2024     WorkSafeBC Efficacy / effectiveness of platelet-rich plasma in treating chronic ankle sprain
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Real time high resolution MR image guidance during irradiation]
2024     NIHR Health Technology Assessment programme Laparoscopic cholecystectomy versus conservative management for adults with uncomplicated symptomatic gallstones: the C-GALL RCT
2024     National Institute for Health and Care Excellence (NICE) CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack. NICE diagnostics guidance 59
2024     National Institute for Health and Care Excellence (NICE) Avapritinib for treating advanced systemic mastocytosis. NICE technology appraisal guidance 1012
2024     WorkSafeBC Causal association between post-concussion syndrome and the development of myalgic encephalomyelitis / chronic fatigue syndrome
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Irreversible electroporation for renal cancer]
2024     NIHR Health Technology Assessment programme Care models for coexisting serious mental health and alcohol/drug conditions: the RECO realist evidence synthesis and case study evaluation
2024     National Institute for Health and Care Excellence (NICE) Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 1010
2024     WorkSafeBC Efficacy and effectiveness of cold compression therapies post-joint surgery
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Algorithm-based Alzheimer's disease diagnosis-aided test using plasma biomarkers]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism by MS/MS. Update: Carnitine uptake deficiency; very long chain acyl-CoA dehydrogenase deficiency]
2024     National Institute for Health and Care Excellence (NICE) Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia. NICE technology appraisal guidance 1013
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – 2nd Addendum to Project A24-73]
2024     WorkSafeBC Causal association between back sprain / strain and spontaneous abortion
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Resuscitative endovascular balloon occlusion of the aorta]
2024     Andalusian Health Technology Assessment Area (AETSA) [Liquid biopsy in lung neoplasms: diagnosis, prognosis and treatment adequacy]
2024     National Institute for Health and Care Excellence (NICE) Belzutifan for treating tumours associated with von Hippel-Lindau disease. NICE technology appraisal guidance 1011
2024     Agency for Care Effectiveness (ACE) Tricuspid transcatheter edge-to-edge repair system for symptomatic severe tricuspid regurgitation
2024     WorkSafeBC Causal association of being a retired firefighter and the development of coronary artery diseases (CAD)
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endoscopic anti-reflux mucosectomy, ARMS]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isoflavone: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Paclitaxel-coated balloon dilatation in recurrent bulbar urethral strictures]
2024     National Institute for Health and Care Excellence (NICE) Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices. NICE diagnostics guidance 61
2024     Agency for Care Effectiveness (ACE) Radiolucent fixation rods & screws for patients with primary and metastatic spinal tumours
2024     WorkSafeBC Causal association between exposure to certain chemicals and the development of idiopathic Parkinson's Disease
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endorectal cooling accompanying prostate cancer surgery]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: imaging of the spine for the investigation of low back pain]
2024     National Institute for Health and Care Excellence (NICE) Digital technologies for assessing attention deficit hyperactivity disorder (ADHD). NICE diagnostics guidance 60
2024     Agency for Care Effectiveness (ACE) Lumbar artificial disc replacement for treatment of patients with lumbar disc degenerative disease
2024     WorkSafeBC Efficacy/effectiveness of prolozone or PEMF in treating shoulder or back strain as well as disc herniation
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Migraine surgery]
2024     NIHR Health Technology Assessment programme Treatment options for patients with pilonidal sinus disease: PITSTOP, a mixed-methods evaluation
2024     National Institute for Health and Care Excellence (NICE) Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction. NICE interventional procedures guidance 794
2024     Agency for Care Effectiveness (ACE) Continuous glucose monitoring systems for children and adults with type 1, monogenic or pancreatogenic diabetes mellitus
2024     WorkSafeBC Pharmacological and psychosocial interventions for ketamine use disorder
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Sirolimus (facial angiofibroma associated with tuberous sclerosis complex, ≥ 6 years)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment discussions: Does shared decision-making between doctor and patient regarding the choice of treatment lead to better results?]
2024     NIHR Health Technology Assessment programme Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis